Department of Radiology, Mayo Clinic, Rochester, MN, USA.
Alzheimers Dement. 2011 Jul;7(4):474-485.e4. doi: 10.1016/j.jalz.2011.04.007.
The promise of Alzheimer's disease biomarkers has led to their incorporation in new diagnostic criteria and in therapeutic trials; however, significant barriers exist to widespread use. Chief among these is the lack of internationally accepted standards for quantitative metrics. Hippocampal volumetry is the most widely studied quantitative magnetic resonance imaging measure in Alzheimer's disease and thus represents the most rational target for an initial effort at standardization.
The authors of this position paper propose a path toward this goal. The steps include the following: (1) Establish and empower an oversight board to manage and assess the effort, (2) adopt the standardized definition of anatomic hippocampal boundaries on magnetic resonance imaging arising from the European Alzheimer's Disease Centers-Alzheimer's Disease Neuroimaging Initiative hippocampal harmonization effort as a reference standard, (3) establish a scientifically appropriate, publicly available reference standard data set based on manual delineation of the hippocampus in an appropriate sample of subjects (Alzheimer's Disease Neuroimaging Initiative), and (4) define minimum technical and prognostic performance metrics for validation of new measurement techniques using the reference standard data set as a benchmark.
Although manual delineation of the hippocampus is the best available reference standard, practical application of hippocampal volumetry will require automated methods. Our intent was to establish a mechanism for credentialing automated software applications to achieve internationally recognized accuracy and prognostic performance standards that lead to the systematic evaluation and then widespread acceptance and use of hippocampal volumetry. The standardization and assay validation process outlined for hippocampal volumetry was envisioned as a template that could be applied to other imaging biomarkers.
阿尔茨海默病生物标志物的前景促使其被纳入新的诊断标准和治疗试验中;然而,广泛使用仍存在重大障碍。其中最主要的是缺乏国际公认的定量指标标准。海马体积测量是阿尔茨海默病最广泛研究的定量磁共振成像测量方法,因此是标准化初始努力的最合理目标。
本文作者提出了实现这一目标的途径。这些步骤包括:(1)建立并授权一个监督委员会来管理和评估这项工作;(2)采用欧洲阿尔茨海默病中心-阿尔茨海默病神经影像学倡议海马协调努力中出现的磁共振成像解剖海马边界的标准化定义作为参考标准;(3)基于适当的受试者样本(阿尔茨海默病神经影像学倡议)中手动描绘海马,建立一个科学合理、公开可用的参考标准数据集;(4)使用参考标准数据集定义新测量技术验证的最小技术和预后性能指标,作为基准。
尽管手动描绘海马是最佳的参考标准,但海马体积测量的实际应用需要自动化方法。我们的目的是建立一个认证自动化软件应用程序的机制,以达到国际公认的准确性和预后性能标准,从而对海马体积测量进行系统评估,然后广泛接受和使用。为海马体积测量制定的标准化和分析验证过程被设想为可以应用于其他成像生物标志物的模板。